20:56 , Jul 15, 2019 |  BC Extra  |  Company News

July 15 Company Quick Takes: Boehringer takes out cancer vaccine company Amal; plus Farxiga setback, Alkermes and more

Boehringer buying cancer vaccine play Amal  Boehringer Ingelheim (Ingelheim, Germany) is acquiring Amal Therapeutics S.A. (Geneva, Switzerland), a University of Geneva spinout developing cancer vaccines. Amal's shareholders will receive an undisclosed upfront payment; the total...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
15:58 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
10:56 , Nov 12, 2018 |  BC Extra  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

BioMedPartners closes third fund at CHF100M

BioMedPartners (Basel, Switzerland) closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany...
18:11 , Mar 1, 2018 |  BC Extra  |  Financial News

BioMedPartners closes third fund

BioMedPartners closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany and neighboring...
16:17 , Sep 8, 2017 |  BC Week In Review  |  Financial News

Amal raises $9.5M in first close of series B round

On Sept. 5, cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) raised €8 million ($9.5 million) in the first close of a series B round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Financial News

Amal Therapeutics completes venture financing

Amal Therapeutics S.A. , Geneva, Switzerland   Business: Cancer   Date completed: 2016-03-30   Type: Venture financing   Raised: CHF3 million ($3.1 million)   Investors: Boehringer Ingelheim Venture Fund; VI Partners; High-Tech Gruenderfonds  ...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

University of Minnesota, Amal Therapeutics deal

The university granted Amal exclusive rights to a patent covering the use of a peptide with immunostimulatory properties when used as an adjuvant for cancer vaccines. The partners did not respond to inquiries. University of...
07:00 , Jun 23, 2014 |  BioCentury  |  Emerging Company Profile

Amal: Party of two

Amal Therapeutics S.A. is developing a platform of recombinant cancer vaccines that may induce a more potent and durable response than earlier vaccines by activating two different cell types important in antitumor immunity and by...